Last edited 02/2021 and last reviewed 02/2021

Prognosis can vary widely but appears to be most dependent on treatment (1)

  • Several randomized, controlled trials have shown that untreated autoimmune hepatitis patients have a 5-year and 10-year survival rate of 50% and 10%, respectively.
  • 60% to 80% of patients will enter remission after the proposed duration of treatment
    • approximately 50% of these patients will relapse requiring therapy resumption

Some patients require life-long immunosuppression.

Treatment failure occurs in 10% of patients that undergo treatment with prednisone.

Those who undergo liver transplantation, approximately a third of patients have a recurrence of autoimmune hepatitis.